at2221
Glycogen Storage Disease Due To Acid Maltase Deficiency, Infantile Onset
UNKNOWNUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Glycogen Storage Disease Due To Acid Maltase Deficiency, Infantile Onset cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alglucosidase Alfa Genzyme, a Sanofi Company | Phase 4 | BB |
Miglustat Amicus Therapeutics | Phase 3 | B |
Cipaglucosidase Alfa Amicus Therapeutics | Phase 3 | B |
gc301 GeneCradle Inc | Phase 1/2 | CCC |
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN) University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
at2221 is also rated in:
glycogen storage disease due to acid maltase deficiency, late-onsetDormant
B
Indicative · Phase 3
62 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →